Fecal pyruvate kinase (M2-PK): A new predictor for inflammation and severity of pouchitis

Walkowiak, Jarosław; Banasiewicz, Tomasz; Krokowicz, Piotr; Hansdorfer-Korzon, Rita; Drews, Michał; Herzig, Karl‐Heinz

doi:10.1080/00365520500319112

Cited by 41 publications

(27 citation statements)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Fecal tumor M2-PK was observed to be increased in association with rectal abscess and ulcerative colitis during studies of colorectal carcinoma. 9 It was proposed as a screening investigation useful for predicting inflammation and severity of pouchitis 22 and subsequent studies have examined its role as an inflammatory marker.…”

Section: Discussionmentioning

confidence: 99%

Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders

Jeffery

Lewis

Ayling

2009

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders

Jeffery

Lewis

Ayling

2009

Inflammatory Bowel Diseases

View full text Add to dashboard Cite

show abstract

“…In a study from our group, serum CRP levels correlated with endoscopic inflammation in the pouch and afferent limb. However, the CRP level as snapshot had a limited role in distinguishing between healthy and diseased pouch conditions diagnosed based on longitudinal clinical and endoscopic evaluation [46].…”

Section: Laboratory Testsmentioning

confidence: 99%

Diagnosis and Management of Pouchitis and Ileoanal Pouch Dysfunction

Navaneethan

Shen

2010

Curr Gastroenterol Rep

View full text Add to dashboard Cite

Restorative proctocolectomy with ileal pouch-anal anastomosis (IPAA) has become the surgical treatment of choice for patients with medically refractory ulcerative colitis (UC) or UC with dysplasia and for the majority of patients with familial adenomatous polyposis. However, UC patients with IPAA are susceptible to inflammatory and noninflammatory sequelae, such as pouchitis, Crohn's disease of the pouch, cuffitis, and irritable pouch syndrome, in addition to common surgery-associated complications, which adversely affect the surgical outcome and compromise health-related quality of life. Pouchitis is the most frequent long-term complication of IPAA in patients with UC, with a cumulative prevalence of up to 50%. Pouchitis may be classified based on the etiology into idiopathic and secondary types, and the management is often different. Pouchoscopy is the most important tool for the diagnosis and differential diagnosis in patients with pouch dysfunction. Antibiotic therapy is the mainstay of treatment for active pouchitis. Some patients may develop dependency on antibiotics, requiring long-term maintenance therapy. Although management of antibiotic-dependent or antibiotic-refractory pouchitis has been challenging, secondary etiology for pouchitis should be evaluated and modified, if possible.

show abstract

“…Fecal M2-PK can be an indicator of IBD [35,36] and some studies showed plasma M2-PK to have elevated levels in acute and serious inflammation disease [37,38] . However, our study did not find that serum M2-PK is a good index for IBD, for three possible reasons.…”

Section: Discussionmentioning

confidence: 99%

Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Meng¹,

Zhu

Xu³

et al. 2012

WJGO

View full text Add to dashboard Cite

Author contributions: Meng W and Zhu HH contributed equally to this work; Meng W conducted the study, data collection, management and analysis, and drafted the manuscript; Zhu HH did data correction, designed the analysis strategy and did data interpretation, co-drafted and revised the manuscript, reviewed and edited the whole manuscript; Xu ZF performed quality control on ELISA work; Cai SR performed previous screening work and collection of serum samples; Dong Q performed helpful work in previous screening; Pan QR did part of ELISA work; Zheng S co-supervised the field activities and designed the study's analytical strategy; Zhang SZ co-designed the study, co-supervised the field activities and did quality assurance and control. METHODS:We conducted a molecular epidemiology study in Hangzhou, China, from year 2006 to year 2008. Serum samples were collected from 93 CRC, 41 advanced adenomas, 137 adenomas, 47 non-adenomatous polyps, and 158 normal participants in a community setting. Serum M2-PK and carcinoembryonic antigen (CEA) were measured using Enzyme-linked immunosorbent assay. SPSS 16.0 software was used to perform data analysis. Area under the receiver operating characteristic curve (AUC), sensitivity, and specificities were estimated for serum M2-PK in diagnosis of colorectal lesions and compared with CEA. RESULTS:Average serum M2-PK value among 158 normal people was 2.96 U/mL and not affected by gender (P = 0.47) or age (P = 0.59). Average serum M2-PK (U/mL) was 14.75 among stage Ⅲ and 13.10 among stage Ⅰ and Ⅱ CRC patients, about 4 times higher than that among normal people. Average serum M2-PK was 8.58, 6.70, 5.13 and 2.51 U/mL among advanced adenoma, adenomas, non-adenomatous polyps, and inflammatory bowel disease patients, respectively. AUC for serum M2-PK was greater than that for CEA among all colorectal lesions. AUC for serum M2-PK was 0.89 (0.84, 0.94) (95% confidence interval), higher than that for CEA [0.70 (0.62-0.79 The diagnostic sensitivity for all colorectal lesions increased with decrease in the cut-off value of serum M2-PK. The diagnostic sensitivity (%) of serum M2-PK was 100.00 for CRC, 95.12 advanced adenoma, 82.48 adenoma, and 82.98 non-adenomatous polyp. There were no CRC cases missed and 40.51% of BRIEF ARTICLE

show abstract

Fecal pyruvate kinase (M2-PK): A new predictor for inflammation and severity of pouchitis

Cited by 41 publications

References 5 publications

Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders

Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders

Diagnosis and Management of Pouchitis and Ileoanal Pouch Dysfunction

Serum M2-pyruvate kinase: A promising non-invasive biomarker for colorectal cancer mass screening

Contact Info

Product

Resources

About